1. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC

2. Activity Goals

3. Patient Case Study

4. Patient History

5. CheckMate 017: Nivolumab vs Docetaxel in Refractory, Squamous, Advanced NSCLCa

6. CheckMate 017: Results in Squamous NSCLC

7. CheckMate 057: Nivolumab vs Docetaxel in Refractory, Advanced Non-squamous NSCLC

8. CheckMate 057: Results

9. Checkpoint Inhibitors Being Evaluated for the First-Line Treatment of NSCLC

10. First-line Treatment of NSCLC

11. PDL1: Challenges in Biomarker Development

12. CheckMate 057: OS Based on PD-L1 Expression

13. CheckMate 057: Response Rates

14. Current Status of PD-1 Inhibitors in Clinical Practice

15. Pembrolizumab in Patients With Brain Metastases: Phase 2 Study

16. Efficacy of Immunotherapy

17. Patient History (Follow-up)

18. Outstanding Issues

19. Immune-Mediated Adverse Events With PD-1 Inhibitors

20. Abbreviations

21. References

22. References (cont)

23. References (cont)

24. References (cont)

25. References (cont)

26. References (cont)

27. References (cont)